StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the stock.
Ayala Pharmaceuticals Stock Up 0.9 %
ADXS stock opened at $0.56 on Wednesday. Ayala Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $1.95. The company has a market cap of $5.97 million, a price-to-earnings ratio of -0.07 and a beta of 1.62. The company has a 50 day moving average of $0.69 and a two-hundred day moving average of $0.74.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last released its earnings results on Tuesday, April 16th. The company reported ($2.96) earnings per share (EPS) for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
See Also
- Five stocks we like better than Ayala Pharmaceuticals
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Invest in Blue Chip Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- The Significance of Brokerage Rankings in Stock Selection
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
